Compare Starbucks Corp (SBUX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Smith & Nephew plc — how do they compare? Starbucks Corp trades at $90.75 (market cap $106.26B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Starbucks Corp is far larger — about 9.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and Smith & Nephew plc for 121 Days on average.
| SBUX | SNN | |
|---|---|---|
Market Cap | $106.26B | $11.10B |
Volume | 30,248,434 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $37.17 |
52-Week Low | $78.46 | $26.42 |
Typical Hold Time | 190 Days | 121 Days |
Enterprise Value | $125.08B | $14.13B |
Dividend Yield | 2.7% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $93.21, down 0.4% on the day, amid a bearish technical signal and recent store closure announcements. The stock shows mixed earnings performance with Q1 and Q2 2026 beats but a Q4 2025 miss, while 2025 revenue grew to $37.18B with a net income margin of 5.17%. Analyst consensus is a Buy with a $115.50 price target, but technical indicators suggest near-term pressure with support at $89 and resistance at $96.
The outlook for SBUX hinges on its turnaround strategy execution, including portfolio optimization through store closures. Upside potential exists from analyst targets, but risks include labor relations, competitive pressures, and macroeconomic sensitivity. The stock's high P/E of 53.88 indicates growth expectations must be met for sustained gains.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
